Abstract:Abstract Chronic pain affects one in five of the general population and is the third most important cause of disability-adjusted life-years globally. Unfortunately, treatment remains inadequate due to poor efficacy and tolerability. There has been a failure in translating promising preclinical drug targets into clinic use. This reflects challenges across the whole drug development pathway, from preclinical models to trial design. Nociceptors remain an attractive therapeutic target: their sensitization makes an important contribution to many chronic pain states, they are located outside the blood–brain barrier, and they are relatively specific. The past decade has seen significant advances in the techniques available to study human nociceptors, including: the use of corneal confocal microscopy and biopsy samples to observe nociceptor morphology, the culture of human nociceptors (either from surgical or post-mortem tissue or using human induced pluripotent stem cell derived nociceptors), the application of high throughput technologies such as transcriptomics, the in vitro and in vivo electrophysiological characterization through microneurography, and the correlation with pain percepts provided by quantitative sensory testing. Genome editing in human induced pluripotent stem cell-derived nociceptors enables the interrogation of the causal role of genes in the regulation of nociceptor function. Both human and rodent nociceptors are more heterogeneous at a molecular level than previously appreciated, and while we find that there are broad similarities between human and rodent nociceptors there are also important differences involving ion channel function, expression, and cellular excitability. These technological advances have emphasized the maladaptive plastic changes occurring in human nociceptors following injury that contribute to chronic pain. Studying human nociceptors has revealed new therapeutic targets for the suppression of chronic pain and enhanced repair. Cellular models of human nociceptors have enabled the screening of small molecule and gene therapy approaches on nociceptor function, and in some cases have enabled correlation with clinical outcomes. Undoubtedly, challenges remain. Many of these techniques are difficult to implement at scale, current induced pluripotent stem cell differentiation protocols do not generate the full diversity of nociceptor populations, and we still have a relatively poor understanding of inter-individual variation in nociceptors due to factors such as age, sex, or ethnicity. We hope our ability to directly investigate human nociceptors will not only aid our understanding of the fundamental neurobiology underlying acute and chronic pain but also help bridge the translational gap.

IUPHAR review: Navigating the role of preclinical models in pain research

Advancing Pain Understanding and Drug Discovery: Insights from Preclinical Models and Recent Research Findings

Animal models of chronic pain: Advances and challenges for clinical translation

Modulating Neural Circuits of Pain in Preclinical Models: Recent Insights for Future Therapeutics

Deciphering pain: molecular mechanisms and neurochemical pathways–challenges and future opportunities

Potential of animal models for advancing the understanding and treatment of pain in Parkinson’s disease

Finding new analgesics: Computational pharmacology faces drug discovery challenges

Studying human nociceptors: from fundamentals to clinic

Molecular and Behavioral Changes in Nociception in a Novel Rat Model of Chronic Pancreatitis for the Study of Pain

The challenges of animal models of pain

Receptor and Molecular Targets for the Development of Novel Opioid and Non-Opioid Analgesic Therapies

Human surrogate models of central sensitization: A critical review and practical guide

Improving Preclinical Development of Novel Interventions to Treat Pain: Insanity Is Doing the Same Thing Over and Over and Expecting Different Results

Neuropathic pain; what we know and what we should do about it

Strategies for measuring non-evoked pain in preclinical models of neuropathic pain: Systematic review

In vitro models for neuropathic pain phenotypic screening in brain therapeutics

Pain research in a petri dish? Advantages and limitations of neuro-glial primary cell cultures from structures of the nociceptive system

Microbiome contributions to pain: a review of the preclinical literature

Navigating Preclinical Models and Medications for Peripheral Neuropathy: A Review

Targeting nociceptive transient receptor potential channels to treat chronic pain: current state of the field

Cellular circuits in the brain and their modulation in acute and chronic pain.